Hip
Senior Member
- Messages
- 18,109
A team in New Zealand have picked up the baton on the universal antiviral DRACO, which might cure ME/CFS and many other diseases linked to viruses, as well fight a wide range of acute and chronic viral infections in humans and animals.
Rick Kiessig and Phil Oliver created a biotech start-up company called Kimer Med to pick up on DRACO where its original inventor Dr Todd Rider left off.
The Kimer Med team have created a derivative of DRACO, which they named VTose, and are planning to test it on the SARS-CoV-2 coronavirus. DRACO has already been successfully tested on 15 different viruses.
At the moment, the team at Kimer Med are asking for people to spread the news on social media, online forums, blogs, etc, which will help with funding and progressing the development of VTose.
So if you have a Twitter account, are a blog writer, are in any relevant Facebook groups, etc, you might like to post a link to this thread, and/or to Kimer Med's website.
The Background to DRACO
DRACO achieves a broad-spectrum elimination of viral infection by targeting an Achilles heel found in most viruses: the dsRNA which viruses produce when they infect cells.
DRACO is drawn into virally-infected cells, because DRACO is designed to target and bind to this viral dsRNA. Once inside these infected cells, DRACO kills the cell.
Works for the majority of viruses, since nearly all viruses generate dsRNA in cells.
DRACO simply consists of two proteins "glued" together: a protein which binds to dsRNA, and a second protein which is able to kill the cell (the second protein causes the cell to undergo cell suicide, aka, apoptosis).
DRACO stands for double-stranded RNA activated caspase oligomerizer.
MIT researcher Todd Rider was unable to get funding to continue his research on DRACO, because pharmaceutical companies are not interested in taking it on, as it is too early in its development cycle to attract commercial pharmaceutical interest.
The only organizations who might invest in DRACO are government research funding agencies, like the National Institutes of Health (NIH) in the US. But these agencies have let Todd Rider's DRACO languish for the last 16 years (if they hadn't, we likely would have had by now the perfect antiviral for the coronavirus pandemic, and for any other pandemic which might hit us future).
There is a Business Insider article which explains why DRACO could not get a research grant.
Todd Rider's 2011 paper on DRACO is here: Broad-Spectrum Antiviral Therapeutics.
Todd Rider's DRACO patent.
If you search Google, you can find many articles on DRACO.
Kimer Med have a discussion forum here, in case anyone wants to read more about VTose research and development.
Rick Kiessig and Phil Oliver created a biotech start-up company called Kimer Med to pick up on DRACO where its original inventor Dr Todd Rider left off.
The Kimer Med team have created a derivative of DRACO, which they named VTose, and are planning to test it on the SARS-CoV-2 coronavirus. DRACO has already been successfully tested on 15 different viruses.
At the moment, the team at Kimer Med are asking for people to spread the news on social media, online forums, blogs, etc, which will help with funding and progressing the development of VTose.
So if you have a Twitter account, are a blog writer, are in any relevant Facebook groups, etc, you might like to post a link to this thread, and/or to Kimer Med's website.
The Background to DRACO
DRACO achieves a broad-spectrum elimination of viral infection by targeting an Achilles heel found in most viruses: the dsRNA which viruses produce when they infect cells.
DRACO is drawn into virally-infected cells, because DRACO is designed to target and bind to this viral dsRNA. Once inside these infected cells, DRACO kills the cell.
Works for the majority of viruses, since nearly all viruses generate dsRNA in cells.
DRACO simply consists of two proteins "glued" together: a protein which binds to dsRNA, and a second protein which is able to kill the cell (the second protein causes the cell to undergo cell suicide, aka, apoptosis).
DRACO stands for double-stranded RNA activated caspase oligomerizer.
MIT researcher Todd Rider was unable to get funding to continue his research on DRACO, because pharmaceutical companies are not interested in taking it on, as it is too early in its development cycle to attract commercial pharmaceutical interest.
The only organizations who might invest in DRACO are government research funding agencies, like the National Institutes of Health (NIH) in the US. But these agencies have let Todd Rider's DRACO languish for the last 16 years (if they hadn't, we likely would have had by now the perfect antiviral for the coronavirus pandemic, and for any other pandemic which might hit us future).
There is a Business Insider article which explains why DRACO could not get a research grant.
Todd Rider's 2011 paper on DRACO is here: Broad-Spectrum Antiviral Therapeutics.
Todd Rider's DRACO patent.
If you search Google, you can find many articles on DRACO.
Kimer Med have a discussion forum here, in case anyone wants to read more about VTose research and development.
Last edited: